LBA7 Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2-expression

作者：Xinan Sheng, Guang‐Zhi Zeng, C. Zhang, Qi Zhang, Jiang Bian, Huifeng Niu, Jian Li, Yue Shi, Kun Yao, Bin Hu, Zhen Liu, Haoran Liao, Zhuang Yu, Boquan Jin, Liling Zhang, Bingqian Liu, Jun Fang, Zihao He, Xiao‐Hua Zhou, Jun Guo · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.09.125 · 被引用次数：4 · 研究领域：Bladder and Urothelial Cancer Treatments、Urinary and Genital Oncology Studies、Renal cell carcinoma treatment